Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for CAPR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 237.93M
March 31, 2026 278.61M
December 31, 2025 318.13M
September 30, 2025 98.57M
June 30, 2025 122.80M
March 31, 2025 144.78M
December 31, 2024 151.52M
September 30, 2024 85.03M
June 30, 2024 29.46M
March 31, 2024 39.92M
December 31, 2023 39.49M
September 30, 2023 28.52M
June 30, 2023 37.79M
March 31, 2023 45.17M
December 31, 2022 41.42M
September 30, 2022 46.61M
June 30, 2022 51.42M
March 31, 2022 58.33M
December 31, 2021 34.89M
September 30, 2021 40.84M
June 30, 2021 38.08M
March 31, 2021 41.88M
December 31, 2020 32.67M
September 30, 2020 35.30M
June 30, 2020 36.25M
Date Value
March 31, 2020 13.22M
December 31, 2019 9.885M
September 30, 2019 7.060M
June 30, 2019 6.124M
March 31, 2019 7.355M
December 31, 2018 7.542M
September 30, 2018 10.79M
June 30, 2018 12.87M
March 31, 2018 13.78M
December 31, 2017 14.87M
September 30, 2017 14.51M
June 30, 2017 13.09M
March 31, 2017 12.87M
December 31, 2016 17.54M
September 30, 2016 21.12M
June 30, 2016 11.35M
March 31, 2016 14.26M
December 31, 2015 13.57M
September 30, 2015 17.22M
June 30, 2015 21.13M
March 31, 2015 24.47M
December 31, 2014 11.01M
September 30, 2014 13.83M
June 30, 2014 16.29M
March 31, 2014 13.86M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
REGENXBIO, Inc. 105.74M
Cytokinetics, Inc. 1.169B
Emergent BioSolutions, Inc. 140.90M
Rigel Pharmaceuticals, Inc. 95.33M
United Therapeutics Corp. 2.662B